| Ticker | ABUS |
|---|---|
| ISIN | CA03879J1003 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (Ga...
Arbutus Biopharma Corporation opera en el sector Healthcare, industria Biotechnology.